4D Medicine has developed a unique, biodegradable polymer that can be 3D printed to create a variety of implantable devices for orthopaedic repairs, nerve repairs, slow drug release, and cosmetic dermal fillers. The company anticipates receiving their first regulatory approval this year. 4D Medicine has already turned down an earn-out acquisition offer of £38 million based solely on the value of the biopolymer, as they firmly believe they can generate greater value by developing their own applications.

4D Medicine is on a mission to revolutionise biomaterials for the medical device market, enhancing patient outcomes through powerful collaborations with dynamic industry partners. By harnessing their unique materials and expertise in resorbable device design, they will team up with established and emerging market players, paving the way for the next generation of implantable resorbable devices across a wide array of medical applications.

Afon Technology introduces Glucowear—the world’s first non-invasive, real-time blood glucose monitor, designed for the diabetic and wellness market. Worn comfortably on the wrist, this innovative device uses microwave signals to deliver pain-free, needle-free readings without delay, ensuring seamless day-to-day management for over 537 million diabetics worldwide.

Backed by cutting-edge AI and deep learning, Glucowear offers accuracy comparable to traditional glucose monitors, without the need for invasive methods. With clinical trials underway in collaboration with leading research centres, Glucowear is on track to transform lives by combining convenience, technology, and health. The future of diabetes care is here.

Established in 2021, Aureum Diagnostics is revolutionising the diagnostic landscape. The company focuses on developing high-performance, low-cost electrochemical biosensing platforms for the $50 billion point of care medical diagnostics market and the $4.9 billion biosafety testing market. Aureum Diagnostics offers a measurement platform that includes a low-cost handheld connected instrument and very affordable single-use disposable test strips. Their tests are as simple and inexpensive as traditional lateral flow tests, yet as accurate as PCR tests, allowing for the detection of multiple biomarkers from a single sample.

With exciting commercial partnerships with Merck and ElectraDx, Aureum has successfully completed a sale of intellectual property worth approximately $50 million and has a revenue-generating strategic co-development partnership with Merck. Designed to surpass current and emerging competitors, Aureum’s diagnostics platforms are truly state-of-the-art.

Biosceptre International is at the forefront of cancer care, leveraging cutting-edge CAR-T immunotherapy to target nfP2X7 - a unique marker found only on cancer cells. Their revolutionary approach precisely destroys cancer cells while sparing healthy ones, minimising the harsh side effects associated with traditional treatments.

With the patented BRiDGE™ CAR technology, Biosceptre amplifies the power of monoclonal antibodies, ensuring more effective cancer cell eradication and reducing the risk of resistance. Backed by Nobel laureate Sir Greg Winter and a portfolio of over 140 patents, Biosceptre is redefining cancer therapy with innovation and impact.

Dxcover is transforming cancer detection with a groundbreaking liquid biopsy platform that pinpoints early-stage tumours from just a drop of blood. Using advanced infrared spectroscopy, Dxcover achieves unmatched sensitivity and specificity, identifying signals beyond the reach of genetic tests.

With its simple "drop, dry, detect" system, Dxcover delivers results in minutes, eliminating the need for specialist labs while being ten times cheaper than current methods. Collaborating with leading European centres and a multi-billion-dollar US company, Dxcover is validating diagnostics for brain and colon cancers, setting a new standard in early detection and effective treatment. Dxcover are changing the future of cancer care.

Glen Clova Scientific (GCS) is revolutionising treatment for dermatological and allergic conditions with its next-generation vaccines. Harnessing Virus-Like Particles (VLPs), GCS activates the immune system to neutralise harmful proteins, offering a more effective and affordable solution than traditional therapies.
 
With only one or two doses annually, minimal drug requirements, and no need for lab monitoring, GCS’ approach is redefining patient care for conditions like asthma, eczema, hay fever, and senile pruritus. Backed by a decade of groundbreaking research and an exclusive partnership with Almirall, GCS is poised for early revenue generation and global impact in improving lives. Experience the future of healthcare innovation with GCS.

Laverock Therapeutics is a gene silencing company that utilises a powerful technology to harness the body’s natural gene regulatory mechanisms. Their goal is to develop a new generation of programmable advanced therapies that are more effective, safer, and more accessible for treating major diseases.

Laverock Therapeutics stands out as one of the most innovative companies in the field of gene therapy. They have developed a novel approach to controlling gene expression that has garnered attention from major pharmaceutical companies, including E. Lilly. Their technology allows for the precise tuning of gene expression, similar to adjusting the volume on a radio, rather than simply turning a gene on or off as current technologies do. This innovative approach has numerous potential applications, with their initial focus on enhancing the latest generation of cancer immunotherapies. Later, they aim to provide “off-the-shelf” cellular therapies for treating diabetes.

Oxford Endovascular introduces OxiFlow™ - the next-generation flow-diverter designed to revolutionise the treatment of brain aneurysms, a condition impacting 1 in 50 people globally. Leveraging advanced origami-inspired engineering, OxiFlow™ unfolds seamlessly to fit against the blood vessel wall, ensuring enhanced precision and reducing risks associated with conventional stents.
 
Founded by world-renowned experts, Professor James Byrne and Professor Zhong You, Oxford Endovascular combines medical innovation with aerospace-level engineering. As the design moves into clinical trials, OxiFlow™ promises a safer, more effective solution for patients worldwide, setting a new benchmark in brain aneurysm care. Oxford Endovascular is redefining brain aneurysm treatment with precision engineering.

Santersus has developed a revolutionary blood purification technique aimed at treating sepsis, autoimmune conditions, and transplanted organs, with potential applications in cancer and Alzheimer’s disease as well. In the past 15 years, it has been discovered that products from white blood cells known as NETs can initiate or worsen these conditions. Santersus’ patented technology effectively removes NETs from the blood using a standard apheresis system.

Santersus has already conducted a First-in-Human trial for treating sepsis, which accounts for 20% of deaths worldwide, and the results have been excellent. They have also received FDA breakthrough status for their NucleoCapture® device. Commercial partnerships have been established with OrganOx to improve transplant organ treatment and with Inus Health to conduct trials for Alzheimer’s disease.

With a world-class team that has a proven track record in generating significant returns, the simplicity and scalability of this system make it suitable for a mass market. The design allows it to be connected to standard plasma separation devices. Terumo, with a market cap of $26 billion, is a global leader in apheresis systems and is collaborating with Santersus as both an investor and partner. This technology has the potential to save millions of lives, and we believe it will also offer exceptional value, making it an outstanding addition to our portfolio.

Secure, smart, and seamlessly connected, Sprite IOT brings cutting-edge technology to life with SpriteGuard™, an innovative plug-and-play system designed to enhance Wi-Fi security, performance, and analytics for the Internet of Things. From monitoring network activity and footfall to tracking environmental factors like CO2 levels, SpriteGuard™ empowers businesses to thrive in data-driven environments.

Whether you're a retail outlet optimising customer insights, a hospitality centre safeguarding public Wi-Fi, or an office enhancing cognitive performance, SpriteGuard™ adapts to your needs. With its CE mark and competitive pricing, Sprite IOT is driving global sales and delivering flexible licensing packages, enabling quick profitability through low overheads.